Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid

Hepatology

Volumn 32, Issue 5, 2000, Pages 897-900

  Angulo, Paul ^a   Patel, Tushar ^a   Jorgensen, Roberta A ^a   Therneau, Terry M ^a   Lindor, Keith D ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; SILYMARIN; URSODEOXYCHOLIC ACID;

ABDOMINAL PAIN; ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BILIARY CIRRHOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; DYSPEPSIA; ENZYME ACTIVITY; FATIGUE; FEMALE; HUMAN; IMMUNOMODULATION; MALE; PRIORITY JOURNAL; PRURITUS; SCORING SYSTEM;

EID: 0033754697     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2000.18663     Document Type: Article

References (40)

1. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis
2. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis
3. The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis
4. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis
5. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis
6. Ursodiol for the long-term treatment of primary biliary cirrhosis
7. Effects of ursodeoxycholic acid on survival of patients with primary biliary cirrhosis
8. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis
9. Does ursodeoxycholic acid improve survival in patients with primary biliary cirrhosis? Comparison of outcome in the U.S. multicenter trial to expected survival using the Mayo Clinic prognostic model
10. Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: A randomized trial
11. Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid
12. Silymarin protects against paracetamol-induced lipid peroxidation and liver damage
13. Stabilization of isolated rat liver plasma membranes by treatment in vitro with silymarin
14. Inhibition of Kupffer cell function as an explanation for the hepatoprotective properties of silibinin
15. Ursodeoxycholic acid influences immune parameters in patients with primary biliary cirrhosis
16. Silybin inhibition of human T-lymphocyte activition
17. Immunomodulatory and hepatoprotective effects of in vivo treatment with free radical scavengers
18. Identification of the antifibrogenic properties of silibinin: Effect on TGF-β and matrix gene expression of hepatic stellate cells
19. Effects of silibinin and antioxidants on high glucose induced alterations of fibronectin turnover in human mesangial cell cultures
20. Effect of silymarin on chemical, functional and morphological alterations of the liver
21. A pilot study on the liver protective effect of silybin-phopshatidyl complex (1dB1016) in chronic active hepatitis
22. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver
23. Prognosis in primary biliary cirrhosis: Model for decision making
24. The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis
25. Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis: Final results of an international trial
26. Factors of prognostic importance in primary biliary cirrhosis
27. Risk factors and prognosis in primary biliary cirrhosis
28. Natural history and prognostic variables in primary biliary cirrhosis (PBC)
29. Is the Mayo risk model for predicting survival useful after the introduction of ursodeoxycholic acid treatment for primary biliary cirrhosis?
30. Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirhosis
31. Serum bilirubin: A prognostic factor in primary biliary cirrhosis
32. Extramural cross-validation of the Mayo primary biliary cirrhosis survival model establishes its generalizability
33. A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis
34. Positive response to methotrexate and ursodeoxycholic acid in patients with primary biliary cirrhosis responding insufficiently to ursodeoxycholic acid alone
35. Methotrexate improves biochemical tests in patients with primary biliary cirrhosis who respond incompletely to ursodiol
36. The combination of ursodeoxycholic acid methotrexate for patients with primary biliary cirrhosis: The results of a pilot study
37. The combination of ursodeoxycholic acid and methotrexate for primary biliary cirrhosis is not better than ursodeoxycholic acid alone
38. Low-dose methotrexate is ineffective in primary biliary cirrhosis: Long-term results of a placebo-controlled trial
39. Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: Results of a prospective double-blind trial
40. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid